Zoetis: The 60% Decline Was Justified, But Shares Are Finally Buyable

Zoetis’ valuation has compressed to 12x trailing earnings after a 52% 12-month share-price decline, reflecting investor concern despite ongoing fundamentals. Growth is decelerating with Q1 2026 revenue up only 3%, though international and livestock help offset weakness in U.S. pet care. The dividend profile remains a key support—12-year growth streak with a 2.8% current yield backed by a solid payout ratio.

Analysis

The market is treating this like a simple de-rating, but the more important mechanism is mix deterioration: if U.S. companion animal demand is the premium-growth engine, then offsetting that with livestock/international can protect reported revenue while still compressing the long-duration multiple. That means the stock can look “cheap” on trailing earnings for a while and still not bottom until investors see evidence that the highest-margin, highest-visibility segment has stabilized.

The second-order effect is competitive rather than absolute demand loss. If veterinarians and pet owners are trading down or delaying purchases, the pressure should ripple first into adjacent animal-health names with heavier U.S. companion exposure, not necessarily into broader healthcare. ELAN is the cleaner read-through on share capture risk, while IDXX matters more if clinic traffic weakens enough to hit diagnostics cadence and consumables.

The dividend is a floor, not a catalyst. A 2.8% yield with a reasonable payout ratio can slow forced selling from income mandates, but it does not reset valuation unless growth reaccelerates; otherwise the stock can stay in a low-teens multiple band for several quarters. The key falsifier is any re-acceleration in U.S. pet care growth on the next two prints, or margin expansion from mix/price that offsets volume weakness.

Over a 1-3 month horizon, this looks more like a watch item than a high-conviction long. Over 6-18 months, if U.S. pet care remains sub-4% and the business keeps leaning on lower-multiple segments, the market may continue to assign ZTS a discount to its historical premium until a clear growth inflection appears.

Key Decisions for Investors

• No new outright long ZTS here; wait for one more quarter of U.S. pet-care normalization before adding. The setup is value-protective, not catalyst-rich, and a low-teens multiple can stay capped if growth remains mid-single-digit or below.
• If already long ZTS, consider trimming into any post-earnings strength and re-enter only if U.S. companion-animal revenue inflects above ~5% y/y. Falsifier: another quarter of sub-4% growth with no margin repair.
• Relative-value idea: short ZTS vs long ELAN on the thesis that weaker U.S. pet demand hurts the incumbent premium multiple more than the lower-multiple challenger. Time horizon 1-3 months; cover if ZTS shows share stabilization or ELAN misses on same-channel trends.
• Use IDXX as the cleaner hedge for a clinic-traffic slowdown: if data points show fewer vet visits rather than just category mix-down, IDXX should outperform ZTS downside on a revenue-duration basis.
• Set an alert on forward guidance, not the dividend. If management raises FY EPS only via buybacks/costs while organic pet-care growth stays muted, treat any valuation bounce as a selling opportunity rather than a re-rating signal.